US03209R1032
© ACCESS Newswire
15.12.2025
AMPH
LISTED
NASDAQ
Amphastar Announces FDA Approval for Teriparatide Injection
News Preview
RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for teriparatide injection, USP 560 mcg/2.24mL (250 mcg/mL) single-patient-use prefilled pen....
Themefolio
Profiler
Peergroup
© ACCESS Newswire
24.11.2025
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals to Present at the 37th Annual Piper Sandler Healthcare Conference
News Preview
RANCHO CUCAMONGA, CA / ACCESS Newswire / November 24, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be participating in an Analyst-Moderated fireside chat at the 37th Annual Piper Sandler Healthcare Conference on Wednesday, December...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
12.11.2025
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
News Preview
RANCHO CUCAMONGA, CA / ACCESS Newswire / November 12, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will be participating in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Wednesday, November 19th, 2025, at 3:30...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© ACCESS Newswire
06.11.2025
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2025
News Preview
Reports Net Revenues of $191.8 million for the Three Months Ended September 30, 2025GAAP net income of $17.4 million, or $0.37 per share, for the third quarterAdjusted non-GAAP net income of $44.7 million, or $0.93 per share, for the third quarterCompany to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, CA / ACCESS Newswir...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© ACCESS Newswire
27.10.2025
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2025
News Preview
RANCHO CUCAMONGA, CA / ACCESS Newswire / October 27, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2025 ended September 30, 2025, after the market closes on Thursday, November 6, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
28.08.2025
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals to Present at the 2025 Wells Fargo Healthcare Conference
News Preview
RANCHO CUCAMONGA, CA / ACCESS Newswire / August 28, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3rd, 2025, at 12:45 pm ET. For...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
12.08.2025
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd.
News Preview
Agreement strengthens proprietary peptide pipeline targeting high-value oncology and ophthalmology indications RANCHO CUCAMONGA, CA / ACCESS Newswire / August 12, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar"), a biopharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprieta...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
11.08.2025
AMPH
LISTED
NASDAQ
Amphastar Announces FDA Approval for Iron Sucrose Injection, USP
News Preview
According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer® for the treatment of iron deficiency anemia in patients with chronic kidney disease RANCHO CUCAMONGA, CA / ACCESS Newswire / August 11, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), a biopharmaceutical...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
07.08.2025
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025
News Preview
- Reports Net Revenues of $174.4 million for the Three Months Ended June 30, 2025- GAAP net income of $31.0 million, or $0.64 per share, for the second quarter- Adjusted non-GAAP net income of $40.9 million, or $0.85 per share, for the second quarter- Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, CA / ACCESS Ne...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
29.07.2025
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 7th, 2025
News Preview
RANCHO CUCAMONGA, CA / ACCESS Newswire / July 29, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its second quarter of 2025 ended June 30, 2025, after the market closes on Thursday, August 7, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
14.07.2025
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals Aims to Quadruple Domestic Manufacturing Capacity at Rancho Cucamonga Headquarters
News Preview
RANCHO CUCAMONGA, CA / ACCESS Newswire / July 14, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), a bio-pharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, has announced a multi-year expansion of its U.S. manufacturing operations at its hea...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
22.05.2025
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
News Preview
RANCHO CUCAMONGA, CA / ACCESS Newswire / May 22, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidewi, EVP of Corporate Administration, will be participating in an Analyst-Moderated fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5th, 2025, at 2:00 pm ET. For...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© ACCESS Newswire
09.05.2025
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference
News Preview
RANCHO CUCAMONGA, CA / ACCESS Newswire / May 9, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat at the 2025 Bank of America Health Care Conference on Wednesday, May 14th, 2025, at 1:40 pm PT. For acces...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
07.05.2025
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
News Preview
Reports Net Revenues of $170.5 Million for the Three Months Ended March 31, 2025 RANCHO CUCAMONGA, CA / ACCESS Newswire / May 7, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended March 31, 2025.First Quarter HighlightsNet revenues of $170.5 milli...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
30.04.2025
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025
News Preview
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 30, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its first quarter of 2025 ended March 31, 2025, after the market closes on Wednesday, May 7th, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Time.To...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
03.04.2025
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
News Preview
RANCHO CUCAMONGA, CA / ACCESS Newswire / April 3, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th, 2025, at 1:30 pm ET....
Themefolio
Profiler
Peergroup
© ACCESS Newswire
28.03.2025
AMPH
LISTED
NASDAQ
International Medication Systems, Ltd. Receives FDA's Drug Shortage Assistance Award
News Preview
Recognized for contributions to address shortage of epinephrine injection, 0.1 mg/mL syringes RANCHO CUCAMONGA, CA / ACCESS Newswire / March 28, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) today announced that International Medication Systems, Ltd. ("IMS"), a subsidiary of Amphastar Pharmaceuticals, Inc. ("Amphastar") r...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
05.03.2025
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals to Present at the Barclays 27th Annual Global Healthcare Conference
News Preview
RANCHO CUCAMONGA, CA / ACCESS Newswire / March 5, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations will be presenting at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12th, 2025, at 10:30 am ET. For access, visit A...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
27.02.2025
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2024
News Preview
Reports Net Revenues of $186.5 Million for the Three Months Ended December 31, 2024 RANCHO CUCAMONGA, CA / ACCESS Newswire / February 27, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months and full year ended December 31, 2024.Fourth quarter HighlightsN...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
20.02.2025
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 27, 2025
News Preview
RANCHO CUCAMONGA, CA / ACCESS Newswire / February 20, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its Fourth quarter of 2024 ended December 31, 2024, after the market closes on Thursday, February 27, 2025, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacif...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
08.01.2025
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2025, at 11:15 am PST. For access, visit Amphastar's Pharmaceuticals website...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
26.11.2024
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference
News Preview
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4th, 2024 at 11:30 am EST. For...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
13.11.2024
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
News Preview
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 3:30 pm GMT. For...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
06.11.2024
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024
News Preview
Reports Net Revenues of $191.2 Million for the Three Months Ended September 30, 2024RANCHO CUCAMONGA, CA / ACCESSWIRE / November 6, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended September 30, 2024.Third quarter HighlightsNet revenues of $191....
Themefolio
Profiler
Peergroup
© ACCESS Newswire
29.10.2024
AMPH
LISTED
NASDAQ
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6, 2024
News Preview
RANCHO CUCAMONGA, CA / ACCESSWIRE / October 29, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2024 ended September 30, 2024, after the market closes on Wednesday, November 6, 2024, and will hold a conference call to discuss its financial results at 2:00 p.m. Pacific Tim...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
